CStone Pharmaceuticals Management
Management criteria checks 4/4
CStone Pharmaceuticals' CEO is Jason Yang, appointed in Aug 2022, has a tenure of 4.08 years. total yearly compensation is CN¥23.73M, comprised of 20.2% salary and 79.8% bonuses, including company stock and options. directly owns 1.36% of the company’s shares, worth $16.40M. The average tenure of the management team and the board of directors is 3.7 years and 5 years respectively.
Key information
Jason Yang
Chief executive officer
CN¥23.7m
Total compensation
| CEO salary percentage | 20.19% |
| CEO tenure | 4.1yrs |
| CEO ownership | 1.4% |
| Management average tenure | 3.7yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -CN¥419m |
| Mar 31 2026 | n/a | n/a | -CN¥428m |
| Dec 31 2025 | CN¥24m | CN¥5m | -CN¥437m |
| Sep 30 2025 | n/a | n/a | -CN¥407m |
| Jun 30 2025 | n/a | n/a | -CN¥377m |
| Mar 31 2025 | n/a | n/a | -CN¥234m |
| Dec 31 2024 | CN¥29m | CN¥5m | -CN¥91m |
| Sep 30 2024 | n/a | n/a | -CN¥117m |
| Jun 30 2024 | n/a | n/a | -CN¥142m |
| Mar 31 2024 | n/a | n/a | -CN¥255m |
| Dec 31 2023 | CN¥58m | CN¥5m | -CN¥367m |
| Sep 30 2023 | n/a | n/a | -CN¥559m |
| Jun 30 2023 | n/a | n/a | -CN¥750m |
| Mar 31 2023 | n/a | n/a | -CN¥827m |
| Dec 31 2022 | CN¥62m | CN¥3m | -CN¥903m |
Compensation vs Market: Jason's total compensation ($USD3.53M) is below average for companies of similar size in the US market ($USD5.22M).
Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.
CEO
Jason Yang (62 yo)
Dr. Jianxin Yang, M.D., Ph D., also known as Jason, serves as President of R&D of CStone Pharmaceuticals since 2024 and was its Senior Vice President and Chief Medical Officer December 2016 until 2024. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President of R&D and Executive Director | 4.1yrs | CN¥23.73m | 1.36% $ 16.4m | |
| CFO & Company Secretary | 3.7yrs | no data | no data | |
| Senior VP & Chief Operating Officer | 2.7yrs | no data | no data | |
| Chief Business & Strategy Officer | 5.3yrs | no data | no data | |
| Senior Vice President of Product Development | 5.3yrs | no data | no data | |
| Senior VP & Chief Medical Officer | 2.7yrs | no data | no data | |
| VP and Head of R&D Management & Chief of Staff to the CEO | less than a year | no data | no data |
Experienced Management: CSPH.F's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President of R&D and Executive Director | no data | CN¥23.73m | 1.36% $ 16.4m | |
| Member of Scientific Advisory Board | 7.5yrs | no data | no data | |
| Non-Executive Director | 5.2yrs | CN¥341.00k | 0.15% $ 1.8m | |
| Independent Non-Executive Director | less than a year | CN¥86.00k | 0.00053% $ 6.4k | |
| Independent Non-Executive Director | 1yr | CN¥93.00k | no data | |
| Non Executive Director | 4.8yrs | CN¥315.00k | 0.16% $ 1.9m | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Non-Executive Chairman | 10.8yrs | CN¥341.00k | 0.085% $ 1.0m | |
| Independent Non-Executive Director | less than a year | no data | no data |
Experienced Board: CSPH.F's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 08:46 |
| End of Day Share Price | 2026/09/04 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CStone Pharmaceuticals is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |
| null null | Guoyuan Securities (HK) Ltd |
| Hanyang Huang | Industrial Securities Co. Ltd. |